Coramitug Biosimilar - Research Grade

Human

TTR

>1mg/ml

IgG1 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P02766

Blue ice

ichor.bio's Coramitug Biosimilar (ICH5449) is an unconjugated, non-therapeutic research-grade analog of the originator antibody coramitug, built around the transthyretin (TTR) target. It is supplied as a human IgG1, kappa molecule for research use only and is not a clinical drug. The originator, coramitug (also known by its development designation PRX004), is a humanized monoclonal antibody being developed for transthyretin amyloidosis, an approach distinguished by its aim to clear existing amyloid deposits rather than only stabilise the native protein. This biosimilar reproduces the target-directed binding activity of that molecule so investigators can use it as a functional reference reagent in vitro. Typical applications include binding characterisation against TTR antigens, neutralisation and aggregate-clearance assays, ADCC and effector-function studies, and use as an isotype-matched or target-specific control alongside other anti-TTR reagents. It is manufactured to research-grade low-endotoxin specifications and is available at scale for reproducible, cost-effective use across assay development and comparability work. It is not intended for therapeutic or diagnostic use in humans. Transthyretin (TTR; UniProt P02766) is a ~55 kDa homotetrameric transport protein synthesised mainly by the liver and choroid plexus. It circulates in plasma and cerebrospinal fluid, where it carries thyroxine (T4) and, via retinol-binding protein, vitamin A. The native tetramer is normally stable, but destabilisation, whether age-related (wild-type) or driven by point mutations (hereditary variants), allows dissociation into monomers that misfold and aggregate into amyloid fibrils. These deposits accumulate in peripheral nerves and the heart, producing the polyneuropathy and cardiomyopathy that define transthyretin amyloidosis (ATTR). Because misfolded and non-native TTR conformers differ from the functional tetramer, they can be selectively recognised by conformation-specific antibodies, which is the basis for antibody approaches that target deposited amyloid and soluble aggregates while sparing the physiological transport protein.

ATTR, Prealbumin, TBPA, Transthyretin, PALB

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Coramitug biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Coramitug biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Coramitug biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Coramitug that binds TTR; for research use only.